Related Experiment Video
Updated: Jun 19, 2026
09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
VEGF: a surrogate marker for peripheral vascular disease
1Vascular and Endovascular Surgery, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany.
Summary
Vascular Endothelial Growth Factor (VEGF) shows promise as a marker for peripheral vascular disease (PVD) severity. Higher pre-treatment VEGF levels in PVD patients correlated with advanced disease stages and poorer outcomes.
Area of Science:
- Biochemistry
- Vascular Biology
- Clinical Medicine
Background:
- Peripheral vascular disease (PVD) is a significant health concern.
- Identifying reliable markers for disease severity is crucial for effective management.
- Vascular Endothelial Growth Factor (VEGF) is implicated in vascular health and disease.
Purpose of the Study:
- To investigate the potential of serum VEGF as a surrogate marker for the severity of peripheral vascular disease (PVD).
- To correlate pre-treatment VEGF levels with clinical parameters and disease stages in PVD patients.
Main Methods:
- Serum VEGF levels were quantified using enzyme-linked immunosorbent assay (ELISA).
- 293 PVD patients and 26 healthy controls were included in the study.
- Clinical parameters and Fontaine stages of PVD were documented.
Main Results:
- Serum VEGF levels showed a strong correlation with Fontaine stages (p<0.006 for stage IV vs. controls).
- Elevated pre-treatment VEGF levels were associated with poorer patient outcomes.
- VEGF levels indicated disease severity in PVD patients.
Conclusions:
- Serum VEGF may serve as a valuable surrogate indicator for assessing PVD severity.
- VEGF levels could aid in predicting patient outcomes in peripheral vascular disease.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:19Imaging Studies VII: Vascular Imaging
DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...